Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Critical Care Commute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Critical Care Commute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Psychedelics: Is it time to change your mind? With Dr James Downer.

17:16
 
Share
 

Manage episode 492584152 series 3526907
Content provided by Critical Care Commute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Critical Care Commute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode, we’re joined by Dr. James Downar, a leading Canadian voice in palliative and critical care, for a wide-ranging discussion on the emerging role of psychedelics in managing psychological and existential distress.

Psychedelics have gone from fringe to forefront in recent years, and we dig into what that shift might mean for patients facing critical illness or the end of life.

What psychedelics are and how they work

  • Substances like psilocybin, LSD, ketamine, and MDMA

  • Key effects: altered perception, ego dissolution, and emotional insight

  • Risks and benefits in vulnerable populations

Psychedelic-assisted therapy: structure and process

  • The three-phase model: preparation, the session itself, and integration

  • Micro dosing vs. full therapeutic sessions

  • Where current evidence stands

Potential applications in critical care and palliative medicine

  • Helping patients process fear, isolation, and suffering

  • How psychedelics differ from traditional symptom management tools like opioids

  • Limitations in advanced illness due to physiological concerns

Research and implementation challenges

  • Problems with study design and placebo controls

  • The importance of ‘set and setting’

  • Defining success in existential or spiritual distress

Ethical considerations and clinical integration

  • Balancing innovation with compassion and caution

  • Avoiding reductionism: why psychedelics should complement—not replace—human care

  • The future role of these therapies in ICU and palliative settings

  continue reading

80 episodes

Artwork
iconShare
 
Manage episode 492584152 series 3526907
Content provided by Critical Care Commute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Critical Care Commute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode, we’re joined by Dr. James Downar, a leading Canadian voice in palliative and critical care, for a wide-ranging discussion on the emerging role of psychedelics in managing psychological and existential distress.

Psychedelics have gone from fringe to forefront in recent years, and we dig into what that shift might mean for patients facing critical illness or the end of life.

What psychedelics are and how they work

  • Substances like psilocybin, LSD, ketamine, and MDMA

  • Key effects: altered perception, ego dissolution, and emotional insight

  • Risks and benefits in vulnerable populations

Psychedelic-assisted therapy: structure and process

  • The three-phase model: preparation, the session itself, and integration

  • Micro dosing vs. full therapeutic sessions

  • Where current evidence stands

Potential applications in critical care and palliative medicine

  • Helping patients process fear, isolation, and suffering

  • How psychedelics differ from traditional symptom management tools like opioids

  • Limitations in advanced illness due to physiological concerns

Research and implementation challenges

  • Problems with study design and placebo controls

  • The importance of ‘set and setting’

  • Defining success in existential or spiritual distress

Ethical considerations and clinical integration

  • Balancing innovation with compassion and caution

  • Avoiding reductionism: why psychedelics should complement—not replace—human care

  • The future role of these therapies in ICU and palliative settings

  continue reading

80 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play